Background: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance. Objective: Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens. Methods: All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks. Results: The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1–5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1–49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides. Conclusions: These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects / A.F. Capetti, G.V. De Socio, M.V. Cossu, G. Sterrantino, G. Cenderello, A. Cattelan, G.M. Baldin, A. Soria, N. Riccardi, F.P. Niero, B.M. Celesia, G. Barbarini, S. Rusconi, G. Rizzardini. - In: HIV CLINICAL TRIALS. - ISSN 1528-4336. - 19:6(2018 Dec), pp. 242-248.
|Titolo:||Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects|
RUSCONI, STEFANO (Penultimo)
|Parole Chiave:||HIV; dolutegravir; darunavir; dual; salvage; simplification|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||dic-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/15284336.2018.1550290|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV 1 infected HTE subjects, HCT 2019.pdf||Publisher's version/PDF||Administrator Richiedi una copia|